CervoMed Inc. (CRVO) Stock Forecast
CRVO analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 5.00 / 5 from 6 analysts
- Price target
- $15.00 average of analyst targets
- Upside to target
- +569.6% from the latest close
- Next earnings
- November 6, 2026 EPS estimate $-0.61
- 52-week range
- $2.24 – $9.94
CRVO analyst ratings
6 analystsNumber of analysts at each rating.
CRVO price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRVO earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.50 | −$0.73 | −$0.23 | −$0.84 | +40.5% | 5 |
| Current fiscal year (2026) | −$2.13 | −$2.97 | −$1.16 | −$2.98 | +28.5% | 5 |
| Next fiscal year (2027) | −$1.39 | −$1.96 | −$0.68 | −$2.13 | +35.0% | 4 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRVO revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $50,000 | $0 | $300,000 | −84.5% | 6 |
| Current fiscal year (2026) | $133,330 | $0 | $800,000 | −96.7% | 6 |
| Next fiscal year (2027) | $833,330 | $0 | $5.0M | +525.0% | 6 |
CRVO EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRVO revenue: reported and forecast
CRVO EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.58 | −$0.55 | −$0.57 | −$0.57 | −$0.50 | −14.5% | 3 up · 1 down |
| Current fiscal year (2026) | −$2.67 | −$2.15 | −$2.20 | −$2.20 | −$2.13 | −20.0% | 3 up · 1 down |
| Next fiscal year (2027) | −$2.32 | −$1.50 | −$1.48 | −$1.48 | −$1.39 | −40.3% | 3 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRVO earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRVO beat in 4 of 12.
What analysts expect from CRVO
6 analysts cover CervoMed; their consensus rating is strong buy (5.00 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.00, 569.6% above the latest close of $2.24. Analysts expect earnings of −$2.13 per share for 2026, +28.5% from a year earlier. For 2027 the average estimate is −$1.39 per share on revenue of $0.8 million. CervoMed beat the EPS estimate in 4 of the last 12 quarters.
Related: CRVO income statement, CRVO key metrics, CRVO chart. See the CRVO stock overview for the latest quote and news.
CRVO forecast FAQ
What is CervoMed's price target?
The average analyst price target for CervoMed is $15.00, 569.6% above the latest close of $2.24.
Is CervoMed a buy, hold or sell?
Of 6 analysts covering CervoMed, 6 rate it a strong buy, 0 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CervoMed's EPS forecast?
Analysts forecast −$2.13 per share for 2026 (range −$2.97 to −$1.16); for 2027 the estimate is −$1.39.
What is CervoMed's revenue forecast?
The average revenue estimate for 2026 is $0.1 million, growth of −96.7%; for 2027 it is $0.8 million.
When does CervoMed report earnings?
CervoMed is expected to report results for the quarter ending September 30, 2026 on November 6, 2026; the EPS estimate is $-0.61.
Does CervoMed usually beat earnings estimates?
CervoMed reported EPS at or above the analyst estimate in 4 of the last 12 quarters.